Yeji
FDA approvaloutcome: successconf 1.00

revuforj — FDA approval

$SNDX · Syndax Pharmaceuticals Inc
Event date
October 24, 2025
225 days ago
Sponsor runway
21 mo
$352.1M liquid

Evidence

“openFDA SUPPL (EFFICACY) approval of REVUFORJ — application NDA218944”
Source ↗

Comparable historical fda approvals· last 5 years · same event type

100% hit rate (10/10)
TickerDrugDateOutcome
$INCYzynyz2026-05-18success
$INCYjakafi xr2026-05-01success
$AXSMauvelity2026-04-30success
$INCYzynyz2026-03-30success
$BIIBspinraza2026-03-27success
$CORTlifyorli2026-03-25success
$RYTMimcivree2026-03-19success
$ASNDyuviwel2026-02-27success
$BMRNpalynziq2026-02-27success
$ETONdesmoda2026-02-25success

Recent insider activity· ±90 days

3 insiders · 0 buys · 4 sells
Gift
2025-12-01
Goldan Keith A.
Chief Financial Officer
1,224 @ ——
Exercise10b5-1
2025-09-08
Metzger Michael A
Chief Executive Officer
157,307 @ $10.90$1.71M
Sell10b5-1
2025-09-08
Metzger Michael A
Chief Executive Officer
157,307 @ $16.41$2.58M
Exercise10b5-1
2025-08-18
Podlesak Dennis
Director
19,200 @ $7.20$138K
Sell10b5-1
2025-08-18
Podlesak Dennis
Director
19,200 @ $15.84$304K
Exercise10b5-1
2025-08-15
Podlesak Dennis
Director
14,400 @ ——
Exercise10b5-1
2025-08-15
Podlesak Dennis
Director
19,200 @ $7.20$138K
Sell10b5-1
2025-08-15
Podlesak Dennis
Director
19,200 @ $15.54$298K
Exercise10b5-1
2025-08-15
Podlesak Dennis
Director
4,800 @ ——
Sell10b5-1
2025-08-14
Podlesak Dennis
Director
19,200 @ $14.19$273K
Exercise10b5-1
2025-08-14
Podlesak Dennis
Director
19,200 @ $7.20$138K
Other
2025-07-31
Goldan Keith A.
Chief Financial Officer
1,226 @ $8.43$10K
← All catalysts for $SNDX